KEYNOTE-B61

Home Tag

Banner web VHIO (1300 × 600 px) (3)

Immunotherapy-based combination of pembrolizumab plus lenvatinib as first-line treatment for patients with advanced non-clear cell renal cell carcinoma

Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…